Afaxys Pharmaceuticals Release: Aubra™ Coverage Expands Significantly

CHARLESTON, SC--(Marketwired - February 20, 2014) - Afaxys Pharmaceuticals' oral contraceptive,

Aubra™ /AW--bruh/ (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.1mg/0.02mg) is an AB rated, generic contraceptive.

• Aubra is AB rated to Lutera® and compares to these monophasic regimens: Sronyx®, Aviane®, Falmina®, Lessina®, Levlite®, and Orsythia®.

Aubra is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive for contraception. This product does not protect against the transmission of HIV (AIDS) and other sexually transmitted diseases. (See black box warning next paragraph).

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiological studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

Please see full prescribing information and black box warning for Aubra here: https://pharma.afaxys.com/afaxys/afcor_web_hcp_aubra.html

Aubra is now covered by California's Family Planning, Access, Care and Treatment (Family PACT) program. The purpose of FPACT (www.FPACT.org) is to provide comprehensive family planning services to low-income men and women; the program serves 18.8 million individuals of child-bearing age.

The Aubra inclusion in FPACT coverage marks a major milestone for Afaxys Pharmaceuticals (https://pharma.afaxys.com/afaxys/afcor_web_default.html), a division of Afaxys Inc., which has a stated mission of serving public health and safety net family planning providers who have long been buffeted by soaring prices and product shortages.

Available only to the public health sector (including family planning clinics; college and university health centers; community health centers; and city, county, state and federal facilities), and authorized, non-retail prescribers, this Afaxys Pharmaceuticals product is now covered under most fee for service Medicaid plans and commercial managed-care formularies.

Afaxys Pharmaceuticals aims to continue to provide high-priority contraceptive products, like Aubra, at low costs to public health family planning providers. As additional contraceptive products become available the company plans to extend its core contraceptive formulary, with the goal of allowing health centers to decrease high inventory costs by purchasing fewer products while still meeting their patients' needs.

Note: This press release was issued in the United States and is intended as reference information for U.S. journalists and customers. The information contained in this Afaxys press release is accurate at the time of issuance, and the company assumes no responsibility for updating the information to reflect subsequent developments.